(COCP) Cocrystal Pharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US19188J3005

COCP: Antiviral, Treatments, HCV, Influenza, Coronavirus, Norovirus

Cocrystal Pharma, Inc. is a biotechnology company specializing in the discovery and development of antiviral therapies for severe and chronic viral diseases. Utilizing structure-based drug design, the company creates small-molecule inhibitors targeting viral replication. Its pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for hepatitis C virus (HCV) in Phase II trials, and CC-42344, a PB2 inhibitor for influenza in Phase I. Additionally, Cocrystal is developing inhibitors for norovirus, a leading cause of gastroenteritis, leveraging a collaboration with Kansas State University. The company has also partnered with Merck to develop influenza A/B antivirals, enhancing its credibility in the field.

Technically, COCPs stock is below its 20 and 50-day SMAs, indicating bearish momentum. The low average volume and ATR suggest reduced volatility. Fundamentally, with a $17.6M market cap and high P/S ratio, the stock may be undervalued despite its early-stage revenue generation. The 3-month forecast anticipates sideways movement with potential dips, yet upside potential exists pending positive clinical developments.

Additional Sources for COCP Stock

COCP Stock Overview

Market Cap in USD 18m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2011-05-19

COCP Stock Ratings

Growth 5y -64.7%
Fundamental -
Dividend 0.0%
Rel. Strength Industry 11
Analysts 4.5/5
Fair Price Momentum 1.19 USD
Fair Price DCF -

COCP Dividends

No Dividends Paid

COCP Growth Ratios

Growth Correlation 3m -76.9%
Growth Correlation 12m 23.4%
Growth Correlation 5y -89.4%
CAGR 5y -27.59%
CAGR/Max DD 5y -0.29
Sharpe Ratio 12m -1.51
Alpha 3.25
Beta 0.70
Volatility 67.59%
Current Volume 10.3k
Average Volume 20d 17k
What is the price of COCP stocks?
As of March 15, 2025, the stock is trading at USD 1.64 with a total of 10,266 shares traded.
Over the past week, the price has changed by -3.33%, over one month by -11.31%, over three months by -18.59% and over the past year by +11.98%.
Is Cocrystal Pharma a good stock to buy?
No, based on ValueRay Analyses, Cocrystal Pharma (NASDAQ:COCP) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -64.67 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COCP as of March 2025 is 1.19. This means that COCP is currently overvalued and has a potential downside of -27.44%.
Is COCP a buy, sell or hold?
Cocrystal Pharma has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy COCP.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for COCP stock price target?
According to ValueRays Forecast Model, COCP Cocrystal Pharma will be worth about 1.3 in March 2026. The stock is currently trading at 1.64. This means that the stock has a potential downside of -18.9%.
Issuer Forecast Upside
Wallstreet Target Price 8.3 407.9%
Analysts Target Price 8.3 407.9%
ValueRay Target Price 1.3 -18.9%